



EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001
Tel: 022-35661373 / 35664530 Email: enquiries@ebnl.org Website: www.ebnl.org
Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

Date: February 11, 2026

To,
The Manager
Listing Department,
Bombay Stock Exchange Limited,
P. J. Tower, Dalal Street,
Mumbai – 400 001

Ref: -Security Code No.524768
Sub: Outcome of Board Meeting

The Board of Directors at their meeting held today i.e. February 11, 2026 has transacted the following items of business:

Unaudited Financial Results for the Quarter ended December 31, 2025:

Pursuant to Regulation 33(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are forwarding herewith a copy of Unaudited Financial Results for the Quarter ended 31.12.2025.

The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 11.02.2026 (i.e today).

We also enclose "Limited Review Report" dated 11.02.2026, issued by Statutory Auditors, M/s. V. Nagarajan & Co., Chartered Accountant(s), FRN No.: 004879N, in respect of Unaudited Financial Results for the Quarter ended 31.12.2025. The results are enclosed.

The Meeting commenced at 01:14 p.m. and concluded at 02:03 p.m.

Kindly take the above on record.

For **EMMESSAR BIOTECH & NUTRITION LIMITED**

M S Raghavan Ayyangar
(Managing Director)

Encl: As above



V NAGARAJAN & CO.

Chartered Accountants

Limited Review Report on unaudited financial results of Emmessar Biotech & Nutrition Limited for the quarter ended 31 December 2025 and year to date results for the period from 01 April 2025 to 31 December 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Emmessar Biotech & Nutrition Limited

1. We have reviewed the accompanying Statement of unaudited financial results of Emmessar Biotech & Nutrition Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2025 and year to date results for the period from 01 April 2025 to 31 December 2025 ("the Statement").

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For V Nagarajan & Co.

Chartered Accountants

ICAI Firm's Registration No.: 004879N

CHERUKUPA
LLY
SHANKAR
Digitally signed by
CHERUKUPALLY
SHANKAR
Date: 2026.02.11
13:58:38 +05'30'

Shankar Cherekupally

Partner

Place: Hyderabad

Date: 11-February-2026

ICAI Membership No.: 252304

ICAI UDIN: 26252304CLRHW8444

EMMESSAR BIOTECH & NUTRITION LIMITED

Regd Office: T-3/2, MIDC, Taloja, Raigad District, Maharashtra State

CIN: L24110MH1992PLC06594229

Email: enquiries@ebnl.org; Website: www.ebnl.org; Phone: 35661373 / 4530

Statement of Unaudited Financial Results for the quarter ended and nine months ended 31st December 2025 (INR in lakhs, except per share data)

Particulars	Unaudited					Audited year ended 31-03-2025
	Quarter Ended			Nine months Ended		
	31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	
Income						
I Revenue from Operations	9.34	9.17	9.60	27.79	51.52	61.09
II Other Income	48.98	53.87	43.38	156.27	140.11	200.87
III Total Income (I + II)	58.32	63.04	52.98	184.06	191.63	261.96
Expenses						
(a) Cost of material consumed	2.75	3.06	2.81	6.96	6.40	6.90
(b) Purchase of Stock-trade	-	-	0.40	-	12.64	12.64
(c) Changes in Inventories of Finished goods	0.79	(0.62)	(0.00)	2.10	(0.30)	(1.36)
(d) Employee Benefit Expenses	32.99	24.12	27.95	81.61	71.89	92.90
(e) Depreciation & Amortisation expenses	2.51	2.51	2.44	7.51	7.32	9.76
(f) Finance cost	0.06	0.06	-	0.19	-	0.06
(g) Other expenses	6.38	19.90	6.34	35.70	24.14	45.24
Total Expenses (IV)	45.47	49.03	39.94	134.06	122.09	166.14
V Profit / (loss) from Operations before tax (III - IV)	12.85	14.02	13.04	50.00	69.54	95.82
VI Exceptional Items	-	-	-	-	-	-
VII Profit / (loss) before Tax	12.85	14.02	13.04	50.00	69.54	95.82
VIII Tax Expense						
1. Current Tax	(3.21)	(3.59)	(3.00)	(12.80)	(16.00)	(27.30)
2. Deferred Tax	2.01	0.97	(14.19)	2.97	(20.93)	(20.17)
3. MAT Credit	-	-	-	-	-	-
4. Excess / (short) provision of earlier years	-	-	5.87	-	5.87	(16.74)
IX Net Profit / (loss) after tax (V - VI)	11.64	11.40	1.72	40.17	38.48	31.62
X Other Comprehensive Income	-	-	-	-	-	(1.06)
XI Total comprehensive income and Other Comprehensive Income	11.64	11.40	1.72	40.17	38.48	30.56
XII Paid-up Equity Share Capital	499.61	499.61	499.61	499.61	499.61	499.61
(Face Value INR 10/- per share)	10.00	10.00	10.00	10.00	10.00	10.00
XIII Other Equity	-	-	-	-	-	271.19
Earning per Shares (Not annualised except year ended)						
Basic (INR)	0.23	0.23	0.03	0.80	0.77	0.61
Diluted (INR)	0.23	0.23	0.03	0.80	0.77	0.61


Notes:

- The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 11th February 2026 and have been subject to Limited Review by the Statutory Auditors. The review report of the Statutory Auditors is being filed with the BSE.
- The Company operates two segments ie. Healthcare and Rent on Leasehold Land.
- No Investors Compliant received during the quarter ended 31st December 2025.
- These Statement have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act, 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).
- The Government of India has, with effect from November 21, 2025, notified the Code on Social Security, 2020, the Occupational Safety, Health and Working Conditions Code, 2020, the Industrial Relations Code, 2020, and the Code on Wages, 2019 (collectively referred to as the "Labour Codes"), which subsume the existing central labour legislations. The Ministry of Labour and Employment released draft rules under the Labour Codes on December 30, 2025, which are yet to be notified. In addition, certain State Governments have notified state-specific rules under the Labour Codes. Based on management's assessment, the provisions of the Labour Codes that are currently in effect do not have a material impact on the financial statements of the Company. The Company will continue to monitor developments in this regard and assess the impact, if any, arising from the remaining provisions upon notification of the final rules and their respective effective dates.
- Figures of previous period/year have been regrouped/rearranged wherever necessary. The impact of the same is not material to the user of the Statement.

For Emmessar Biotech & Nutrition Limited

Srinivasa Raghavan

Srinivasa Raghavan Mathurakavi Ayyangar
Managing Director
DIN: 00090266



Mumbai
11th February 2026

EMMESSAR BIOTECH & NUTRITION LIMITED							
Regd Office: T-3/2, MIDC, Taloja, Raigad District, Maharashtra State							
CIN: L24110MH1992PLC06594229							
Email: enquiries@ebnl.org; Website: www.ebnl.org; Phone: 35661373 / 4530							
Segmentwise Revenue, Results and Capital Employed for the Quarter and Nine Months Ended 31st Dec 2025 (INR in lakhs, except per share data)							
Sr. No	Particulars	Unaudited					Audited
		Quarter Ended			Nine Months ended		Year Ended
		31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
1	Segment Revenue						
a	Healthcare	9.34	9.17	9.60	27.79	51.52	61.09
b	Rent on leasehold land	41.33	41.33	37.16	123.98	111.48	152.36
c	Others	7.65	12.54	6.22	32.29	28.63	48.51
	Total:	58.32	63.04	52.98	184.06	191.63	261.96
	Less: Inter Segment Revenue	-	-	-	-	-	-
	Net Sales / Income from Operations	58.32	63.04	52.98	184.06	191.63	261.96
2	Segment Results (Profit / Loss) before tax						
a	Healthcare	5.80	6.74	6.39	18.72	32.78	39.12
b	Rent on leasehold land	41.10	41.10	36.93	123.29	110.79	151.44
c	Others	7.65	12.54	6.22	32.29	28.63	48.51
	Total:	54.55	60.38	49.54	174.30	172.20	239.07
	Less:						
	Interest	-	-	-	-	-	-
	Other Unallocable Expenditure (net off)	41.69	46.36	36.50	124.30	102.66	143.25
	Total Profit before Tax	12.85	14.02	13.04	50.00	69.54	95.82
3	Capital Employed (Segment Assets - Segment Liabilities)						
a	Healthcare	10.68	12.77	11.90	10.68	11.90	13.83
c	Rent on leasehold land	(3.28)	(3.05)	(2.35)	(3.28)	(2.35)	-2.59
d	Others	768.46	755.31	735.74	768.46	735.74	767.03
	Total:	775.86	765.02	745.29	775.86	745.29	778.27
<p>Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature.</p> <p>The above results were taken on record at a meeting of the Board of Directors held on 11th February, 2026.</p>							
Mumbai 11th February 2026		 <p>For Emmessar Biotech & Nutrition Limited</p> <p><i>Srinivasa Raghavan Mathurakavi Ayyangar</i></p> <p>Srinivasa Raghavan Mathurakavi Ayyangar Managing Director DIN: 00090266</p>					